Truist Securities initiated coverage on Longboard Pharmaceuticals, Inc. (LBPH) with a Buy rating and a $60 price target, citing its CNS-focused biotech platform and the potential of its lead drug bexicaserin to disrupt the epilepsy market. The analyst believes bexicaserin’s superior safety profile and comparable efficacy to current market leader Fintepla could lead to market share gains and market expansion.